ANGEL YEAST(600298) 长江商报·2025-05-27 23:19Core Viewpoint - Angel Yeast is advancing its biotechnology development by launching a core technology project for serum-free cell culture media, with an estimated total investment of 230 million yuan, aiming to transform its business from a fermentation raw material supplier to a provider of integrated solutions in the biotechnology field [1][2]. Group 1: Biotechnology Development - The company plans to implement a core technology project for serum-free cell culture media, targeting the preparation needs for antibodies, vaccines, and recombinant proteins [2]. - The project will upgrade the existing synthetic biology pilot platform at the Yichang High-tech Zone and add new preparation platforms for serum-free cell culture media and core raw material purification [2]. - The project is expected to have an annual production capacity of 200 tons of dry powder serum-free cell culture media and 100,000 liters of liquid serum-free cell culture media, with a construction period of 30 months and production expected to start in 2027 [2]. Group 2: Financial Performance - In 2024, Angel Yeast is projected to achieve a revenue of 15.197 billion yuan, representing a year-on-year growth of 11.86%, and a net profit of 1.325 billion yuan, with a growth of 4.07% [3]. - For the first quarter of this year, the company reported total revenue of 3.794 billion yuan, an increase of 8.95%, and a net profit of 370 million yuan, up 16.02% year-on-year [3]. Group 3: Product Expansion - The company is expanding its product boundaries, having developed yeast protein that has been included in the new food raw material directory by the National Health Commission [4]. - Angel Yeast's yeast protein is exported to over 40 countries and regions and is used in various food products, including protein powders and dietary supplements [4]. - The company is also constructing a large-scale PHA (polyhydroxyalkanoates) industrialization project, which is seen as an ideal alternative to traditional plastics [4].